Irit Gliko-Kabir
Chief Tech/Sci/R&D Officer at BIOLINERX LTD.
Irit Gliko-Kabir active positions
Companies | Position | Start | End |
---|---|---|---|
BIOLINERX LTD. | Chief Tech/Sci/R&D Officer | 2017-08-31 | - |
Career history of Irit Gliko-Kabir
Former positions of Irit Gliko-Kabir
Companies | Position | Start | End |
---|---|---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Chief Tech/Sci/R&D Officer | 2014-06-30 | - |
Training of Irit Gliko-Kabir
The Hebrew University of Jerusalem | Doctorate Degree |
Statistics
International
Israel | 4 |
Operational
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
BIOLINERX LTD. | Health Technology |
Private companies | 1 |
---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Stock Market
- Insiders
- Irit Gliko-Kabir
- Experience